At AACR Annual Meeting 2026, investigators presented phase II INFINITY cohort results evaluating tremelimumab (Imjudo) plus durvalumab (Imfinzi) as an alternative to surgery for resectable gastric or gastroesophageal junction cancers with high microsatellite instability. In cohort two, 18 enrolled patients received tremelimumab plus durvalumab with intensive surveillance every 12 weeks for two years. Two years after treatment, evaluable efficacy data showed a 71% clinical complete response rate and a 94.1% progression-free survival rate among 17 assessed patients, with no treatment discontinuations and no grade 4/5 adverse events reported. The presentation also included ctDNA exploratory findings, including clearance in most ctDNA-positive patients after therapy, alongside quality-of-life results that did not show significant deterioration.